Diabetes Devices Market - Growth (Size, Share), Segments, Regions, Competition & Trends Overview

The Diabetes Care Devices Market is Segmented by Management Devices (Insulin Pumps, Insulin Syringes, and More), Monitoring Devices (Self-Monitoring Blood Glucose and Continuous Glucose Monitoring), by Patient Type (Type-1 Diabetes, Type-2 Diabetes and More), by End User (Hospitals & Clinics, Home-Care Settings and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD) and Volume (units).

Diabetes Care Devices Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Diabetes Care Devices Market with other markets in Healthcare Industry

Diabetes Care Devices Market Analysis by Mordor Intelligence

The Diabetes Care Devices Market size is estimated at USD 65.74 billion in 2025, and is expected to reach USD 91.95 billion by 2030, at a CAGR of 6.94% during the forecast period (2025-2030).

A closer link between those population dynamics and unit demand emerges as payers, providers and manufacturers increasingly recognize that technology-enabled care lowers lifetime treatment costs. Executives weighing expansion strategies can infer that every incremental percentage point increase in the diagnosed population translates into a disproportionately larger uptick in technology adoption because most newly diagnosed individuals today start their journey with at least one connected device rather than legacy finger-stick meters.

Key Report Takeaways

  • By device type, Monitoring Devices dominated with 65.01% market share in 2024, while Management Devices are projected to register an 8.07% CAGR through 2030.
  • By patient type, Type-2 Diabetes commanded 88.35% market share in 2024 and is simultaneously the fastest-growing segment with a 9.07% CAGR from 2025-2030.
  • By end-user, Hospitals & Clinics led with 55.1% market share in 2024, whereas Home-care Settings are expected to expand at a 7.89% CAGR to 2030.
  • By region, North America held 40.71% of 2024 revenue; Asia is forecast to accelerate at an 8.19% CAGR between 2025-2030.

Segment Analysis

By Device Type: Monitoring Technologies Drive Market Evolution

The monitoring devices segment commands a dominant 65.01% market share in 2024, reflecting its critical role in diabetes management across all patient populations. Continuous glucose monitoring (CGM) systems are revolutionizing diabetes care through real-time data provision and integration with automated insulin delivery systems, fundamentally changing treatment paradigms. A study published in the Journal of Diabetes Science and Technology demonstrated that CGM use is associated with lower HbA1c levels and improved outcomes, though disparities in access persist based on race and socioeconomic status Liebertpub. The management devices segment, encompassing insulin pumps, pens, and syringes, is projected to grow at a faster rate of 8.07% CAGR from 2025-2030, driven by innovations in automated insulin delivery systems and smart insulin pens.

Technological convergence is reshaping the competitive landscape, with integration between monitoring and management devices creating comprehensive diabetes management ecosystems. The emergence of hybrid closed-loop systems that combine CGM data with automated insulin delivery represents a significant advancement, with studies showing improvements in time-in-range metrics and quality of life for users. A clinical trial of the Omnipod 5 automated insulin delivery system in adults with type 2 diabetes demonstrated a significant reduction in hemoglobin A1c levels from 8.2% to 7.4% after 13 weeks, indicating improved glycemic control JAMA Network Open. The development of non-invasive glucose monitoring technologies, including optical and electromagnetic sensors, promises to further transform the market by addressing patient discomfort associated with traditional monitoring methods.

Diabetes Care Devices Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Patient Type: Type-2 Diabetes Dominates and Drives Growth

Type-2 diabetes represents the largest patient segment with an overwhelming 88.35% market share in 2024, while simultaneously exhibiting the fastest growth trajectory at 9.07% CAGR through 2030. This dual dominance reflects the global epidemic of type-2 diabetes, driven by increasing obesity rates, sedentary lifestyles, and aging populations. The management of type-2 diabetes is evolving beyond traditional approaches, with continuous glucose monitoring (CGM) increasingly recognized as valuable for this patient population. Stanford Medicine researchers have developed an AI-based algorithm that utilizes data from continuous blood glucose monitors to identify subtypes of Type 2 diabetes with approximately 90% accuracy, enabling more personalized treatment approaches.

The rise of GLP-1 receptor agonists is creating new dynamics in the type-2 diabetes devices market, with increased demand for glucose monitoring among patients using these medications. A study published in the Journal of Shoulder and Elbow Surgery found that GLP-1 users have a higher likelihood of developing adhesive capsulitis (odds ratio = 1.28), highlighting the need for comprehensive monitoring during treatment Science Direct. Type-1 diabetes and gestational diabetes segments, though smaller, are driving innovation in specialized devices tailored to their unique needs. The development of hybrid closed-loop systems for pediatric type-1 diabetes patients has shown significant improvements in glycemic control, with a study reporting a 0.4% reduction in HbA1c and an 8.4 percentage point increase in time spent in the target glucose range compared to sensor-augmented pump therapy.

By End-user: Home-care Settings Gain Momentum

Hospitals & Clinics currently lead the end-user segment with a 55.1% market share in 2024, benefiting from established infrastructure and specialized diabetes care teams. However, Home-care Settings are experiencing faster growth at 7.89% CAGR from 2025-2030, reflecting the paradigm shift toward patient-centered, remote diabetes management. This transition is accelerated by advancements in telehealth and connected diabetes devices that enable effective remote monitoring and intervention. A Stanford Medicine study implemented an AI-powered dashboard to help diabetes educators identify patients needing assistance by analyzing CGM data efficiently, resulting in 64% of patients achieving optimal A1c levels after one year, compared to 28% in previous cohorts .

The integration of artificial intelligence with home diabetes management is creating new possibilities for personalized care. AI algorithms can predict glucose levels up to 30 minutes in advance, enabling proactive management and reducing the risk of severe glycemic events. Ambulatory Surgical Centers represent a smaller but growing segment, particularly for procedures related to insulin pump implantation and management of diabetes complications. The COVID-19 pandemic accelerated the shift toward home-based care, with patients and providers recognizing the benefits of remote monitoring and telehealth consultations for routine diabetes management. This trend is likely to persist and expand as technologies improve and reimbursement policies adapt to support home-based care models, fundamentally reshaping the end-user landscape for diabetes devices.

Diabetes Care Devices Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America maintains a 40.71 % share in 2024, partially owing to Medicare reimbursement and a high density of device-trained endocrinologists. In that same year the CDC recorded 29.7 million diagnosed and 8.7 million undiagnosed cases of diabetes in the United States (same CDC citation). This sizable undiagnosed cohort provides a latent expansion pool that device makers can target via screening initiatives tied to retail pharmacies. Yet mounting pressure from employers and government payers to reduce healthcare spending suggests future price compression for premium platforms, nudging manufacturers toward value-based-care contracts. 

Asia-Pacific posts the fastest growth at 8.19 % CAGR through 2030, driven by urbanization and the world’s highest absolute number of diabetes cases. International Diabetes Federation estimates place the region’s share above 60 % of global prevalence. Manufacturing executives often overlook that Asia-Pacific also boasts some of the world’s most digitally engaged populations, so smartphone-tethered CGM models may leapfrog earlier Bluetooth-only variants. Consequently, suppliers that embed local language AI coaching into their apps stand to win disproportionately high market share. 

Europe sustains a stable presence thanks to universal health systems and aging demographics. The region’s regulatory environment, guided by the European Medicines Agency, traditionally demands longer trial follow-ups than the FDA, which can delay commercialization. The recent Abbott–Dexcom patent truce removes a legal overhang that previously cast uncertainty on procurement timelines, giving hospital buyers clearer visibility into multi-year supply contracts. An astute reading of the situation suggests that European buyers will now leverage the presence of two legally unencumbered suppliers to negotiate bulk-purchase discounts, compressing average selling prices but potentially boosting unit volumes. 

Diabetes Care Devices Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market concentration is moderate, with three multinational corporations capturing a majority share yet facing nimble startups in sensor miniaturization and algorithm design. The Abbott–Dexcom ten-year cross-license agreement exemplifies a new era of “coopetition,” wherein rivals share foundational intellectual property to accelerate overall market expansion. Medtronic’s partnership with Abbott on an integrated CGM-pump portfolio further evidences the pivot to interoperable ecosystems. Strategists may recognize that partnerships of this nature often presage joint ventures in manufacturing or cloud data analytics, areas where scale provides tangible cost advantages. 

White-space opportunities are emerging at the intersection of diabetes care and obesity pharmacotherapy. GLP-1 receptor agonists reduce glucose excursions, potentially lowering device usage frequency, yet they also heighten the need for periodic titration. Companies integrating weight-management metrics into insulin-dosing algorithms could command premium pricing among endocrinology clinics that treat metabolic syndrome holistically. 

Diabetes Care Devices Industry Leaders

  1. Abbott Diabetes Care

  2. Medtronic (Diabetes)

  3. Dexcom

  4. Roche Diabetes Care

  5. Insulet Corporation

  6. *Disclaimer: Major Players sorted in no particular order
Diabetes Care Devices Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • April 2025: Medtronic received FDA clearance to pair its Simplera Sync sensor with selected insulin pumps, reinforcing its integrated-system roadmap.
  • April 2025: Dexcom secured FDA authorization for the G7 15 Day CGM, extending its sensor life and improving inventory turns.
  • February 2025: Tandem’s Control-IQ+ algorithm gained FDA clearance for Type 2 diabetes, opening a substantial new revenue stream for the company.
  • December 2024: Abbott and Dexcom signed a ten-year cross-license accord, removing litigation costs and accelerating product innovation.
  • November 2024: Medtronic launched an upgraded InPen app, setting the stage for a Simplera CGM-enhanced smart-MDI ecosystem.
  • October 2024: Senseonics received FDA clearance for the Eversense 365, the first implantable sensor approved for annual wear.

Table of Contents for Diabetes Care Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rapid reimbursement expansion for CGM Worldwide
    • 4.2.2 Increasing Global prevalence of diabetes and associated risk factors
    • 4.2.3 advancements in technology
    • 4.2.4 Increased Government and Private Investments
    • 4.2.5 European paediatric guidelines accelerating hybrid closed-loop pump uptake
    • 4.2.6 Off-label GLP-1 surge fuelling home glucose testing demand in North America
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Devices
    • 4.3.2 Less Awareness about Device usage in remote and underdeveloped region
    • 4.3.3 EU-MDR re-certification backlog for legacy lancets
    • 4.3.4 Patch-pump recalls dampening uptake in Oceania
  • 4.4 Supply-Chain Analysis
  • 4.5 Regulatory & Technological Outlook
  • 4.6 Porter’s Five Forces
    • 4.6.1 Threat of New Entrants
    • 4.6.2 Bargaining Power of Buyers
    • 4.6.3 Bargaining Power of Suppliers
    • 4.6.4 Threat of Substitutes
    • 4.6.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value & Volume)

  • 5.1 By Device Type
    • 5.1.1 Monitoring Devices
    • 5.1.1.1 Self-Monitoring
    • 5.1.1.1.1 Blood Glucose
    • 5.1.1.1.2 Glucometer Devices
    • 5.1.1.1.3 Test Strips
    • 5.1.1.1.4 Lancets
    • 5.1.1.2 Continuous Glucose Monitoring
    • 5.1.1.2.1 Sensors
    • 5.1.1.2.2 Durables
    • 5.1.2 Management Devices
    • 5.1.2.1 Insulin Pumps
    • 5.1.2.1.1 Insulin Pump Device
    • 5.1.2.1.2 Insulin Pump Reservoir
    • 5.1.2.1.3 Infusion Set
    • 5.1.2.2 Insulin Syringes
    • 5.1.2.3 Insulin Pens
    • 5.1.2.4 Jet Injectors
  • 5.2 By Patient Type
    • 5.2.1 Type-1 Diabetes
    • 5.2.2 Type-2 Diabetes
    • 5.2.3 Gestational & Others
  • 5.3 By End-user
    • 5.3.1 Hospitals & Clinics
    • 5.3.2 Home-care Settings
    • 5.3.3 Ambulatory Surgical Centres
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 France
    • 5.4.2.3 Italy
    • 5.4.2.4 Spain
    • 5.4.2.5 United Kingdom
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 Japan
    • 5.4.3.2 South Korea
    • 5.4.3.3 China
    • 5.4.3.4 India
    • 5.4.3.5 Australia
    • 5.4.3.6 Vietnam
    • 5.4.3.7 Malaysia
    • 5.4.3.8 Indonesia
    • 5.4.3.9 Philippines
    • 5.4.3.10 Thailand
    • 5.4.3.11 Rest of Asia-Pacific
    • 5.4.4 Latin America
    • 5.4.4.1 Mexico
    • 5.4.4.2 Brazil
    • 5.4.4.3 Rest of Latin America
    • 5.4.5 Middle East and Africa
    • 5.4.5.1 Saudi Arabia
    • 5.4.5.2 Iran
    • 5.4.5.3 Egypt
    • 5.4.5.4 Oman
    • 5.4.5.5 South Africa
    • 5.4.5.6 Rest of Middle East and Africa

6. Competitive Landscape

  • 6.1 Strategic Moves
  • 6.2 Market Share Analysis
  • 6.3 Company profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments
    • 6.3.1 Abbott Diabetes Care
    • 6.3.2 Roche Diabetes Care
    • 6.3.3 Dexcom
    • 6.3.4 Medtronic
    • 6.3.5 Insulet Corporation
    • 6.3.6 Novo Nordisk
    • 6.3.7 LifeScan (Johnson & Johnson)
    • 6.3.8 Ascensia Diabetes Care
    • 6.3.9 Tandem Diabetes Care
    • 6.3.10 Senseonics Holdings
    • 6.3.11 Ypsomed
    • 6.3.12 Terumo
    • 6.3.13 Becton, Dickinson & Co.
    • 6.3.14 Bionime Corporation
    • 6.3.15 Rossmax International
    • 6.3.16 Trividia Health
    • 6.3.17 Nipro Corporation
    • 6.3.18 ARKRAY
    • 6.3.19 Menarini Diagnostics
    • 6.3.20 Sanofi

7. Market Opportunities & Future Outlook

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Diabetes Care Devices Market Report Scope

As per the scope of the report, Diabetes care devices are the hardware, equipment, and software used by diabetes patients to regulate blood glucose levels, prevent diabetes complications, lessen the burden of diabetes, and enhance the quality of life.

The diabetes care devices market is segmented by device type, patient type, end user, and geography. By device type, the market is segmented into monitoring devices and management devices. The monitoring devices are further classified as self-monitoring blood glucose and continuous glucose monitoring. Self-monitoring blood glucose are further divided as glucometer devices, test strips, and lancets, and continuous glucose monitoring includes sensors and durables. By management devices the market is segmented as insulin pumps, insulin syringes, insulin pens, and jet injectors. The insulin pumps are further classified as insulin pump device, insulin pump reservoir, and infusion set. By patient type includes Type-1 diabetes, Type-2 diabetes, and gestational & others. The end users includes hospitals & clinics, home-care settings, and ambulatory surgical centers. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America. For each segment, the market sizing and forecasts have been done based on value (USD). 

By Device Type Monitoring Devices Self-Monitoring Blood Glucose
Glucometer Devices
Test Strips
Lancets
Continuous Glucose Monitoring Sensors
Durables
Management Devices Insulin Pumps Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes
Insulin Pens
Jet Injectors
By Patient Type Type-1 Diabetes
Type-2 Diabetes
Gestational & Others
By End-user Hospitals & Clinics
Home-care Settings
Ambulatory Surgical Centres
Geography North America United States
Canada
Mexico
Europe Germany
France
Italy
Spain
United Kingdom
Rest of Europe
Asia-Pacific Japan
South Korea
China
India
Australia
Vietnam
Malaysia
Indonesia
Philippines
Thailand
Rest of Asia-Pacific
Latin America Mexico
Brazil
Rest of Latin America
Middle East and Africa Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle East and Africa
By Device Type
Monitoring Devices Self-Monitoring Blood Glucose
Glucometer Devices
Test Strips
Lancets
Continuous Glucose Monitoring Sensors
Durables
Management Devices Insulin Pumps Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes
Insulin Pens
Jet Injectors
By Patient Type
Type-1 Diabetes
Type-2 Diabetes
Gestational & Others
By End-user
Hospitals & Clinics
Home-care Settings
Ambulatory Surgical Centres
Geography
North America United States
Canada
Mexico
Europe Germany
France
Italy
Spain
United Kingdom
Rest of Europe
Asia-Pacific Japan
South Korea
China
India
Australia
Vietnam
Malaysia
Indonesia
Philippines
Thailand
Rest of Asia-Pacific
Latin America Mexico
Brazil
Rest of Latin America
Middle East and Africa Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle East and Africa
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current global diabetes care devices market size?

The market is valued at USD 65.74 billion in 2024.

How fast is the diabetes care devices market expected to grow?

Market size is forecast to expand at a 6.94 % CAGR from 2025 to 2030, reaching USD 91.95 billion.

Which region will register the highest growth?

The Asia-Pacific market size is projected to rise at an 8.19 % CAGR between 2025 and 2030.

What device category is growing fastest?

Management devices, especially automated insulin delivery systems, will grow around 8.07 % per year through 2030.

Why are CGM reimbursement policies critical to market share?

Expanded coverage increases patient affordability, accelerating uptake and boosting manufacturer revenue.

How are interoperability regulations affecting competition?

FDA interoperability pathways allow pumps, CGMs and algorithms from different brands to work together, shifting competitive focus from closed hardware ecosystems to software and data integration.

Diabetes Care Devices Market Report Snapshots